-
Mashup Score: 0Investigational CAR T Product GD2-CART01 Displays Safety and Efficacy in Pediatric Neuroblastoma - 1 year(s) ago
Treatment with the third-generation CAR T-cell agent GD2-CART01 was safe and feasible for patients aged 1 to 25 years with relapsed or refractory high-risk neuroblastoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Investigational CAR T Product GD2-CART01 Displays Safety and Efficacy in Pediatric Neuroblastoma - 1 year(s) ago
Treatment with the third-generation CAR T-cell agent GD2-CART01 was safe and feasible for patients aged 1 to 25 years with relapsed or refractory high-risk neuroblastoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Investigational CAR T Product GD2-CART01 Displays Safety and Efficacy in Pediatric Neuroblastoma #oncology #nursing #neuroblastoma #CART #pediatriccancer https://t.co/bPlTlTcYsl
-
-
Mashup Score: 0Survival in Patients With Neuroblastoma on Reduced Therapy as a Result of Change in COG Risk Stratification - The ASCO Post - 1 year(s) ago
By Matthew Stenger Posted: 5/4/2023 9:53:00 AM Last Updated: 5/4/2023 11:25:05 AM In an analysis reported in the Journal of Clinical Oncology, Bender et al found that “excellent” survival outcomes were achieved in patients receiving reduced treatment for neuroblastoma as a result of reassignment to…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Survival in Patients With Neuroblastoma on Reduced Therapy Due to Change in COG Risk Stratification https://t.co/DdjA63uF2U #btsm #neuroblastoma #oncology
-
-
Mashup Score: 2
By Matthew Stenger Posted: 4/12/2023 11:44:00 AM Last Updated: 4/12/2023 11:35:30 AM In a single-institution Italian phase I/II trial reported in The New England Journal of Medicine, Del Bufalo et al found that treatment with chimeric antigen receptor (CAR) T cells targeting the disialoganglioside GD2…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
GD2-CAR T Cells for Relapsed or Refractory High-Risk Neuroblastoma https://t.co/6yM9WgIh3m #btsm #neuroblastoma #oncology #immunotherapy
-
-
Mashup Score: 1Evolutionary Duration of Neuroblastoma Predicts Clinical Outcome - 1 year(s) ago
The length of evolution can accurately predict clinical outcome of neuroblastoma tumors.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read Cancer Discovery's #ResearchWatch: The Evolutionary Duration of #Neuroblastoma Predicts Clinical Outcome, a summary of the paper by Verena Körber, Frank Westermann, Thomas Höfer et al. https://t.co/XwBU8Fqm2V @DKFZ @UniHeidelberg https://t.co/GZevQBiDwJ
-
-
Mashup Score: 0CAR T-Cell Therapy Feasible, Safe in Advanced Neuroblastoma - 1 year(s) ago
ORR of 63% with GD2-targeting product in kids with relapsed, refractory high-risk disease
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
#Immunotherapy with a #CAR T-cell treatment targeting #GD2 may have a sustained #antitumor effect in at least a proportion of #pediatric patients with relapsed or refractory high-risk #neuroblastoma, as well as a favorable safety profile. #OncoTwitter https://t.co/RVDeJL4ro9
-
-
Mashup Score: 0
A novel chimeric antigen receptor T-cell therapy induced clinically impactful antitumor responses in 63% of younger patients with relapsed or refractory, high-risk neuroblastoma, results of a phase 1/phase 2 trial showed.The findings, published in The New England Journal of Medicine, suggest the investigational agent also has a manageable safety profile similar to other CAR T-cell therapies,
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Breakthrough Study shows ‘CAR T CELLS CAN ERADICATE SOLID TUMORS in advanced neuroblastoma. https://t.co/5NuYCbYJz0 #CellTherapyNext #HemOnc #OncAlert #MedEd @Unicatt @Stanford #neuroblastoma
-
-
Mashup Score: 5Lorlatinib found to be safe and effective for patients with ALK-driven relapsed/refractory high-risk neuroblastoma - 1 year(s) ago
In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children’s Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
Lorlatinib found to be safe and effective for #patients with ALK-driven relapsed/refractory high-risk #neuroblastoma @NatureMedicine https://t.co/4dFdU5H1yI
-
-
Mashup Score: 14Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome - Nature Genetics - 1 year(s) ago
Somatic evolutionary analysis of neuroblastoma, a pediatric tumor, proposes a common fetal time of origin. Notably, high-risk tumors exhibit early genomic instability and prolonged evolution, and this evolutionary duration predicts clinical outcomes.
Source: NatureCategories: General Medicine News, Latest HeadlinesTweet-
Predicting #neuroblastoma outcomes with molecular evolution @NatureGenet https://t.co/w85qbn9JBP https://t.co/RgtrE5MyzM
-
-
Mashup Score: 8Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome - Nature Genetics - 1 year(s) ago
Somatic evolutionary analysis of neuroblastoma, a pediatric tumor, proposes a common fetal time of origin. Notably, high-risk tumors exhibit early genomic instability and prolonged evolution, and this evolutionary duration predicts clinical outcomes.
Source: NatureCategories: Genetics, Latest HeadlinesTweet-
🚀 ONLINE @NatureGenet 📰 Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome 🧑🏽🤝🧑🏻 Verena Körber, Frank Westermann, Thomas Höfer, and team ⬇️ https://t.co/sd3hBjfQHN #neuroblastoma @NatResCancer
-
Treatment with the third-generation CAR T-cell agent GD2-CART01 was safe and feasible for patients aged 1 to 25 years with relapsed or refractory high-risk neuroblastoma. #oncology #nursing #neuroblastoma #CART #pediatriccancer https://t.co/blFM0ny82Q